Feature | May 26, 2015

Mitralign Presents Six-Month Data on Mitral Percutaneous Annuloplasty System at EuroPCR 2015

Company seeking CE mark for mitral/tricuspid repair valve in 2015

May 26, 2015 — At EuroPCR 2015, Mitralign presented updates on its mitral and tricuspid valve repair systems, including a presentation on six-month data on its Mitral system.

The Mitralign Percutaneous Annuloplasty System (MPAS) is not approved for sale or distribution; however it is currently being evaluated in clinical trials for a CE mark indication. The MPAS for tricuspid regurgitation is not approved for sale or distribution, but is anticipated to begin clinical investigation in 2015.

Updates on Mitralign’s percutaneous programs were available in the following presentations:

  • Transcatheter mitral valve therapies; new rings, anchors, and techniques;
  • First-in-man of a transcatheter tricuspid valve in a severely regurgitant tricuspid valve patient;
  • Mitralign procedure: A step-by-step case demonstration; and
  • Cardiovascular innovation pipeline – Mitral and tricuspid valve intervention.


Georg Nickenig, M.D., presented “Mitralign CE mark six month data” during the Mitralign Symposium, chaired by Azeem Latib, M.D., and Ted Feldman, M.D. Nickenig was joined by Joachim Schofer, M.D., and Rebecca Hahn, M.D., providing their experience with the Mitralign Percutaneous Annuloplasty System for tricuspid regurgitation.

Unlike other approaches, the Mitralign Percutaneous Annuloplasty System uses wires and catheters to deliver pledgets to create plications and tighten the annulus, reduce valve circumference and bring the leaflets closer together.

For more information: www.mitralign.com

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init